2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13D.01 Prognostic Factors and Outcomes of Large Cell Neuroendocrine Carcinoma of Lung: A Single Center Retrospective Cohort Study

EP.13D.01 Prognostic Factors and Outcomes of Large Cell Neuroendocrine Carcinoma of Lung: A Single Center Retrospective Cohort Study

Back to course

Pdf Summary

The study "Prognostic Factors and Outcomes of LCNEC," conducted at Queen Elizabeth Hospital in Hong Kong, explored the clinical characteristics, treatment modalities, and outcomes of patients with large cell neuroendocrine carcinoma of the lung (LCNEC). This rare and aggressive cancer is historically noted for poor outcomes and is underrepresented in clinical trials, leading to gaps in understanding its molecular landscape and optimal treatments.<br /><br />The retrospective cohort study reviewed 41 LCNEC patients treated between 2000 and 2022. The cohort predominantly consisted of males (35) and presented a strong association with smoking. Most patients had locally advanced disease (N disease) at diagnosis, with only a third presenting with distant metastases. Definitive treatments were administered to 25 patients, including surgery and chemoirradiation, with the common use of etoposide-platinum based chemotherapy post-surgery.<br /><br />The study found that LCNEC has a high recurrence rate post-treatment, with a median recurrence time of 9.2 months and a 5-year recurrence-free survival rate of only 9.3%. The median overall survival (OS) was 23.9 months for surgically treated patients and 14.8 months for those who received chemoirradiation. Patients ineligible for definitive treatment, who mostly received palliative systemic therapy, displayed a median OS of 6.9 months.<br /><br />Molecular diagnostics were conducted on 20 patients, revealing druggable mutations in six, including EGFR mutations, ALK overexpression, and RET translocation. These mutations allowed for targeted therapies using tyrosine kinase inhibitors, showing variable responses.<br /><br />In conclusion, LCNEC remains an aggressively recurrent form of non-small cell lung cancer, but the identification of actionable mutations offers promising avenues for personalized treatment. This study underscores the importance of further research into targeted therapies for LCNEC to potentially improve clinical outcomes.

Asset Subtitle

Leone Sutanto

Meta Tag

Speaker Leone Sutanto

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

LCNEC

large cell neuroendocrine carcinoma

lung cancer

prognostic factors

treatment outcomes

molecular diagnostics

EGFR mutations

tyrosine kinase inhibitors

personalized treatment

targeted therapies